Clinical Trial: NCT04718883
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Information Provided By: | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Last Update Posted: | 2023-11-24 |
Study Overview
Brief Summary
This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.
Official Title
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Conditions
Mantle Cell Lymphoma
Intervention / Treatment
- Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Other Study ID Numbers
- JWCAR029-005
Start Date (Actual)
2021-01-13
Primary Completion Date (Actual)
2023-10-25
Study Completion Date (Estimated)
2028-08-07
Enrollment (Actual)
59
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Information Provided By: | Shanghai Ming Ju Biotechnology Co., Ltd. |
| Last Update Posted: | 2023-11-24 |
Study Overview
Brief Summary
This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.
Official Title
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Conditions
Mantle Cell Lymphoma
Intervention / Treatment
- Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Other Study ID Numbers
- JWCAR029-005
Start Date (Actual)
2021-01-13
Primary Completion Date (Actual)
2023-10-25
Study Completion Date (Estimated)
2028-08-07
Enrollment (Actual)
59
Study Type
Interventional
Phase
Phase 2